Alexza’s AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of … - Biloxi Sun Herald
MOUNTAIN VIEW, Calif., Dec. 9 /PRNewswire-FirstCall/ — Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced positive results from its second Phase 3 clinical trial of AZ-004 (Staccato(R) loxapine). This Phase 3 clinical trial was conducted in …